Active — Not RecruitingNot Applicable

Assessing Claims of Cannabis as an Anti-cancer Agent (CATA)

United States50 participantsStarted 2021-03-19

Plain-language summary

The purpose of the study is to find out how cannabis may help control cancer growth by reviewing medical records of patients who report cannabis helped treat their cancer.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * diagnosed with cancer * have used any type of cannabis/marijuana, including those with cannabidiol (CBD) and/or tetrahydrocannabinol (THC) to treat their cancer * believe that cannabis has either stopped the tumor from growing and/or caused a cancer antigen blood marker to remain stable or cannabis has shrunken the tumor and/or caused reduction in a cancer antigen blood marker Exclusion Criteria: * does not have cancer * has not used any type of cannabis/marijuana, including those with CBD and/or THC to treat their cancer * does not believe that cannabis has either stopped the tumor from growing and/or caused a cancer antigen blood marker to remain stable or cannabis has shrunken the tumor and/or caused reduction in a cancer antigen blood marker

What they're measuring

To successfully complete Phase 2 by recruiting patients to consent with a simplified screening survey.

Timeframe: From enrollment start to the obtainment of cancer diagnosis and treatment details and cannabis use history from each consented patient, which is estimated to take up to 6 years.

Trial details

NCT IDNCT07107607

SponsorHealthPartners Institute

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-01

View on ClinicalTrials.gov More Cancer trials